Helius Medical Technologies, Inc.
Biotech — develops, licenses, and acquires unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. Its first product is the Portable Neuromodulation Stimulator (PoNS™), a device that when used together with physical therapy has been shown to treat gait deficit due to multiple sclerosis. It can also be used in combination with physical therapy to treat chronic balance deficit due to mild-to-moderate traumatic brain injury.
Helius Medical Technologies is listed on the TSX under the symbol HSM.
Three reasons to invest in Helius Medical
- Helius wants to penetrate 20% of the market in Canada by 2024, representing revenue of approximately $50 million — even if Helius only achieves half of that, it will generate an enterprise value in the hundreds of millions of dollars.
- With a market cap of $18 million, Helius is trading at about 8.5 times earnings per share — with medical device companies typically trading at approximately 20 times earnings, we see tremendous upside for the company.
- On May 12, 2020 Helius’ PoNS device was granted “Breakthrough Device” Designation by the FDA in the United States, where the target market is 10 times larger than in Canada — this means the company’s valuation has the potential to increase exponentially over the next several years.